7 results
Search Results
Now showing 1 - 7 of 7
Publication Metadata only Personalised randomised controlled trial designs—a new paradigm to define optimal treatments for carbapenem-resistant infections(2021-06-01) A. Sarah Walker; Ian R. White; Rebecca M. Turner; Li Yang Hsu; Tsin Wen Yeo; Nicholas J. White; Mike Sharland; Guy E. Thwaites; Faculty of Tropical Medicine, Mahidol University; Oxford University Clinical Research Unit; St George’s, University of London; National University of Singapore; Nuffield Department of Medicine; Nanyang Technological University; MRC Clinical Trials Unitaeruginosa. Numerous areas of clinical uncertainty surround the treatment of these highly resistant infections, yet substantial obstacles exist to the design and conduct of treatment trials for carbapenem-resistant bacterial infections. These include the lack... an analogy in network meta-analysis, which compares multiple treatments in an evidence synthesis to rank the best of a set of available treatments. To address these obstacles, we propose extending the network meta-analysis approach to individual randomisationPublication Metadata only The threat of antimalarial drug resistance(2015-01-01) Borimas Hanboonkunupakarn; Nicholas J. White; Mahidol University; Nuffield Department of Clinical Medicinemajor obstacle to malaria control and jeopardizing renewed hopes for elimination. As 2016 is the first year under WHO Global Technical Strategy for Malaria 2016-2030, it is a good time to ponder the progress of both sides and plan for the future.Publication Metadata only Protein profiling of mefloquine resistant Plasmodium falciparum using mass spectrometry-based proteomics(2015-11-30) Onrapak Reamtong; Krongkan Srimuang; Naowarat Saralamba; Polkit Sangvanich; Nicholas P J Day; Nicholas J. White; Mallika Imwong; Mahidol University; Chulalongkorn University; University of Oxfordleading to higher morbidity and mortality of malaria than the other four species. Antimalarial resistance is the major obstacle to control malaria. Mefloquine was used in combination with Artesunate for uncomplicated P. falciparum in South East AsiaPublication Metadata only Mass primaquine treatment to eliminate vivax malaria: Lessons from the past(2014-02-07) Anatoly Kondrashin; Alla M. Baranova; Elizabeth A. Ashley; Judith Recht; Nicholas J. White; Vladimir P. Sergiev; Sechenov First Moscow State Medical University; Mahidol University; Churchill HospitalRecent successes in malaria control have put malaria eradication back on the public health agenda. A significant obstacle to malaria elimination in Asia is the large burden of Plasmodium vivax, which is more difficult to eliminate than PlasmodiumPublication Metadata only Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy(2001-01-01) Rose McGready; Thein Cho; Samuel; Leopoldo Villegas; Alan Brockman; Michele Van Vugt; Sornchai Looareesuwan; Nicholas J. White; François Nosten; Shoklo Malaria Research Unit; Mahidol University; John Radcliffe Hospital; University of Amsterdam; Instituto de Altos Estudios en Salud Pública;. Adherence to the 7-day regimen and cost (US$18.50 per treatment) are likely to be the main obstacles to this regimen.Publication Metadata only Introducing the concept of a new pre-referral treatment for severely ill febrile children at community level: A sociological approach in Guinea-Bissau(2014-02-06) Audrey Vermeersch; Anaëlle Libaud-Moal; Amabelia Rodrigues; Nicholas J. White; Piero Olliaro; Melba Gomes; Elizabeth A. Ashley; Pascal Millet; Developpements Analytiques et Pharmaceutiques Appliques aux Maladies Negligees et Aux Contrefacons; Projecto de Saúde de Bandim; Mahidol University; Churchill Hospital; Organisation Mondiale de la Santeauthorities. The main obstacles to implementation were the very limited human and financial resources. In the two villages surveyed, 44% of the mothers associated severe illness with fever only, or fever plus one additional symptom. Mothers' judgementPublication Metadata only Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison(2006-06-24) Frank Smithuis; Moe Kyaw Kyaw; Ohn Phe; Khin Zarli Aye; Lhin Htet; Marion Barends; Niklas Lindegardh; Thida Singtoroj; Elizabeth Ashley; Saw Lwin; Kasia Stepniewska; Nicholas J. White; Médecins Sans Frontières (Holland); Shoklo Malaria Research Unit; Mahidol University; Churchill Hospitalobstacles to widespread deployment. To assess whether dihydroartemisinin-piperaquine is a suitable alternative to artesunate-mefloquine, we compared the safety, tolerability, efficacy, and effectiveness of the two regimens for the treatment of uncomplicated